NYSE · Consumer Staples
MEDIFAST INC (MED)
As-reported financials and recent SEC filings for MEDIFAST INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$385.8M
Net income
$-18.7M
Net margin
-4.8%
Diluted EPS
$-1.70
ROE
-9.4%
P/E (TTM)
—
Market cap
$116.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $385.8M | $602.5M | $1.07B | $1.60B | $1.53B |
| Gross profit | $275.2M | $444.6M | $775.9M | $1.14B | $1.13B |
| Operating income | $-14.2M | $2.9M | $126.4M | $184.8M | $216.2M |
| Net income | $-18.7M | $2.1M | $99.4M | $143.6M | $164.0M |
| Diluted EPS | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-01
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →32026-05-28
View on EDGAR →Go deeper on MED
Search MEDIFAST INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.